Impax Asset Management Group
SRPT icon

Impax Asset Management Group’s Sarepta Therapeutics SRPT Stock Holding History

Impax Asset Management Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,412
Closed -$223K – 428
2021
Q3 		$223K Buy
+2,412
New +$186K ﹤0.01% 396
2021
Q1 		– Sell
-2,267
Closed -$387K – 405
2020
Q4 		$387K Buy
+2,267
New +$336K ﹤0.01% 277

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Impax Asset Management Group's SRPT Position: Q4 2021 in Review

Impax Asset Management Group sold out of Sarepta Therapeutics (SRPT) in Q4 2021, closing a stake of 2,412 shares — an estimated $223K sold.

Impax Asset Management Group first reported a position in SRPT in Q4 2020 and held it in 2 quarters. The position peaked at $387K in Q4 2020. 343 funds tracked by Wall St. Rank hold SRPT as of Q4 2021.

  • Impax Asset Management Group reported no remaining Sarepta Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Impax Asset Management Group sold 2,412 Sarepta Therapeutics shares in Q4 2021, an estimated $223K.
  • Impax Asset Management Group first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 2 quarters.
  • Impax Asset Management Group's Sarepta Therapeutics position peaked at $387K in Q4 2020.
  • 343 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2021.

Based on Impax Asset Management Group's 13F filing for Q4 2021, filed 14 Feb 2022.